Literature DB >> 14712313

Vaccine-induced CD8+ T cells eliminate tumors by a two-staged attack.

Dariusz W Kowalczyk1, Anthony P Wlazlo, Wynetta Giles-Davis, Andreas R Kammer, Sunil Mukhopadhyay, Hildegund C J Ertl.   

Abstract

Data presented here demonstrate that vaccine-induced CD8(+) T cells can eliminate their specific tumor-target with a two-staged attack. First, they release interferon-gamma that results in growth arrest of the tumor cells via induction of antiangiogenic mediators. Then, during the latter stages of the immune response, CD8(+) effector T cells eradicate the remaining tumor cells through perforin-mediated lysis. A combination of these two mechanisms is highly effective in the described model, while either pathway alone fails to completely achieve tumor rejection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14712313     DOI: 10.1038/sj.cgt.7700653

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  6 in total

Review 1.  Intravital imaging of CD8+ T cell function in cancer.

Authors:  Thorsten R Mempel; Christian A Bauer
Journal:  Clin Exp Metastasis       Date:  2008-07-30       Impact factor: 5.150

2.  DICE: A novel tumor surveillance mechanism-a new therapy for cancer?

Authors:  Marcus E Peter
Journal:  Cell Cycle       Date:  2014-04-01       Impact factor: 4.534

3.  The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells.

Authors:  Jon G Quatromoni; Eiji Suzuki; Olugbenga Okusanya; Brendan F Judy; Pratik Bhojnagarwala; Ollin Venegas; Evgeniy Eruslanov; Jarrod D Predina; Steven M Albelda; Sunil Singhal
Journal:  BMC Immunol       Date:  2013-07-17       Impact factor: 3.615

Review 4.  The role of CD95 and CD95 ligand in cancer.

Authors:  M E Peter; A Hadji; A E Murmann; S Brockway; W Putzbach; A Pattanayak; P Ceppi
Journal:  Cell Death Differ       Date:  2015-02-06       Impact factor: 15.828

5.  Antibody-activated trans-endothelial delivery of mesoporous organosilica nanomedicine augments tumor extravasation and anti-cancer immunotherapy.

Authors:  Tinglei Huang; Shuang Li; Jianchen Fang; Fuli Li; Shuiping Tu
Journal:  Bioact Mater       Date:  2021-01-14

6.  Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy.

Authors:  Xiaoxue Xie; Yi Feng; Hanxi Zhang; Qingqing Su; Ting Song; Geng Yang; Ningxi Li; Xiaodan Wei; Tingting Li; Xiang Qin; Shun Li; Chunhui Wu; Xiaojuan Zhang; Guixue Wang; Yiyao Liu; Hong Yang
Journal:  Bioact Mater       Date:  2022-03-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.